Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-002917
Filing Date
2025-04-07
Accepted
2025-04-07 07:30:25
Documents
74
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 2018057
2 ex23-1.htm EX-23.1 5655
3 ex31-1.htm EX-31.1 18399
4 ex31-2.htm EX-31.2 18480
5 ex32-1.htm EX-32.1 9183
6 ex32-2.htm EX-32.2 8988
7 ex23-1_001.jpg GRAPHIC 7320
  Complete submission text file 0001641172-25-002917.txt   8079426

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE asbp-20241231.xsd EX-101.SCH 55052
9 XBRL CALCULATION FILE asbp-20241231_cal.xml EX-101.CAL 47628
10 XBRL DEFINITION FILE asbp-20241231_def.xml EX-101.DEF 385793
11 XBRL LABEL FILE asbp-20241231_lab.xml EX-101.LAB 451923
12 XBRL PRESENTATION FILE asbp-20241231_pre.xml EX-101.PRE 430671
76 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 965831
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41293 | Film No.: 25816365
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)